The Medical Advisor

Introduction Access to effective, cancer-specific therapies remains limited, particularly in low- and middle-income countries where cancer survival rates lag behind those in high-income settings due to inadequate funding and infrastructure ( source ,  source ). This has led to increased interest in repurposing existing drugs as more affordable alternatives. Exploring such options may provide valuable insights and potential solutions for expanding treatment accessibility, warranting further scientific investigation. Traditional cancer therapies—including surgery, chemotherapy, radiation, targeted therapy, and immunotherapy—have relatively low documented survival rates and outcomes for advanced, metastatic and stage 4 cancers: Stage 4 Breast Cancer 5-year relative survival rate: 26% (distant/metastatic) ( 2 ). Stage 4 Colorectal Cancer 5-year survival rate: 13% (distant) ( 2 ). Lung Cancer (Stage III NSCLC): Addition of immunotherapy after chemo-radiation increased 3-year survival to...